Polymorphisms in XPD gene could predict clinical outcome of platinum-based chemotherapy for non-small cell lung cancer patients: A meta-analysis of 24 studies

PLoS ONE

Volumn 8, Issue 11, 2013, Pages

  Qin, Qin ^a   Zhang, Chi ^a   Yang, Xi ^a   Zhu, Hongcheng ^a   Yang, Baixia ^b   Cai, Jing ^b   Cheng, Hongyan ^a   Jianxin, Ma ^c   Lu, Jing ^a   Zhan, Liangliang ^a   Liu, Jia ^a   Liu, Zheming ^a   Xu, Liping ^a   Sun, Xinchen ^a  

^a THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

^b NANTONG TUMOR HOSPITAL   (China)

^c Department of Radiation Oncology No2 People's Hospital of Lian Yungang   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; GEMCITABINE; NAVELBINE; PACLITAXEL; PLATINUM DERIVATIVE; XERODERMA PIGMENTOSUM GROUP D PROTEIN;

ARTICLE; ASIAN; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CAUCASIAN; DRUG RESPONSE; ETHNIC DIFFERENCE; HUMAN; LUNG NON SMALL CELL CANCER; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; SINGLE NUCLEOTIDE POLYMORPHISM; STATISTICAL ANALYSIS; SYSTEMATIC REVIEW; TREATMENT OUTCOME; XPD GENE;

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE-FREE SURVIVAL; HUMANS; LUNG NEOPLASMS; ORGANOPLATINUM COMPOUNDS; POLYMORPHISM, SINGLE NUCLEOTIDE; TREATMENT OUTCOME; XERODERMA PIGMENTOSUM GROUP D PROTEIN;

EID: 84896697720     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0079864     Document Type: Article

References (47)

1. Jemal A, Thomas A, Murray T, Thun M (2002) Cancer statistics, 2002. CA Cancer J Clin 52: 23-47. (Pubitemid 34110469)
2. Parkin DM, Pisani P, Ferlay J (1999) Estimates of the worldwide incidence of 25 major cancers in 1990. Int J Cancer 80: 827-841. (Pubitemid 29108856)
3. Einhorn LH (2008) First-line chemotherapy for non-small-cell lung cancer: is there a superior regimen based on histology? J Clin Oncol 26: 3485-3486.
4. Ardizzoni A, Boni L, Tiseo M, Fossella FV, Schiller JH, et al. (2007) Cisplatin-versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis. J Natl Cancer Inst 99: 847-857.
5. Liu L, Wu C, Wang Y, Zhong R, Duan S, et al. (2011) Combined effect of genetic polymorphisms in P53, P73, and MDM2 on non-small cell lung cancer survival. J Thorac Oncol 6: 1793-1800.
6. Liu L, Wu J, Zhong R, Wu C, Zou L, et al. (2012) Multi-loci analysis reveals the importance of genetic variations in sensitivity of platinum-based chemotherapy in non-small-cell lung cancer. Mol Carcinog.
7. Liu L, Wu J, Wu C, Wang Y, Zhong R, et al. (2011) A functional polymorphism (-1607 1G - >2G) in the matrix metalloproteinase-1 promoter is associated with development and progression of lung cancer. Cancer 117: 5172-5181.
8. Ke J, Zhong R, Zhang T, Liu L, Rui R, et al. (2013) Replication study in Chinese population and meta-analysis supports association of the 5p15.33 locus with lung cancer. PLoS One 8: e62485.
9. van de Vaart PJ, Belderbos J, de Jong D, Sneeuw KC, Majoor D, et al. (2000) DNA-adduct levels as a predictor of outcome for NSCLC patients receiving daily cisplatin and radiotherapy. Int J Cancer 89: 160-166. (Pubitemid 30185925)
10. Wu Q, Christensen LA, Legerski RJ, Vasquez KM (2005) Mismatch repair participates in error-free processing of DNA interstrand crosslinks in human cells. EMBO Rep 6: 551-557.
11. Azuma K, Komohara Y, Sasada T, Terazaki Y, Ikeda J, et al. (2007) Excision repair cross-complementation group 1 predicts progression-free and overall survival in non-small cell lung cancer patients treated with platinum-based chemotherapy. Cancer Sci 98: 1336-1343. (Pubitemid 47241754)
12. Gurubhagavatula S, Liu G, Park S, Zhou W, Su L, et al. (2004) XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy. J Clin Oncol 22: 2594-2601. (Pubitemid 41103746)
13. Lord RV, Brabender J, Gandara D, Alberola V, Camps C, et al. (2002) Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin Cancer Res 8: 2286-2291. (Pubitemid 34753602)
14. Spitz MR, Wu X, Wang Y, Wang LE, Shete S, et al. (2001) Modulation of nucleotide excision repair capacity by XPD polymorphisms in lung cancer patients. Cancer Res 61: 1354-1357. (Pubitemid 34292555)
15. Duell EJ, Wiencke JK, Cheng TJ, Varkonyi A, Zuo ZF, et al. (2000) Polymorphisms in the DNA repair genes XRCC1 and ERCC2 and biomarkers of DNA damage in human blood mononuclear cells. Carcinogenesis 21: 965-971. (Pubitemid 30265141)
16. Lunn RM, Helzlsouer KJ, Parshad R, Umbach DM, Harris EL, et al. (2000) XPD polymorphisms: effects on DNA repair proficiency. Carcinogenesis 21: 551-555. (Pubitemid 30214005)
17. Isla D, Sarries C, Rosell R, Alonso G, Domine M, et al. (2004) Single nucleotide polymorphisms and outcome in docetaxel-cisplatin-treated advanced non-small-cell lung cancer. Ann Oncol 15: 1194-1203. (Pubitemid 39199306)
18. Tibaldi C, Giovannetti E, Vasile E, Mey V, Laan AC, et al. (2008) Correlation of CDA, ERCC1, and XPD polymorphisms with response and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. Clin Cancer Res 14: 1797-1803. (Pubitemid 351469466)
19. Mathiaux J, Le Morvan V, Pulido M, Jougon J, Begueret H, et al. (2011) Role of DNA repair gene polymorphisms in the efficiency of platinum-based adjuvant chemotherapy for non-small cell lung cancer. Mol Diagn Ther 15: 159-166.
20. Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR (2007) Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 8: 16.
21. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, et al. (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92: 205-216.
22. Altman DG, Bland JM (2003) Interaction revisited: the difference between two estimates. BMJ 326: 219. (Pubitemid 36143396)
23. Furuta T, Ueda T, Aune G, Sarasin A, Kraemer KH, et al. (2002) Transcription-coupled nucleotide excision repair as a determinant of cisplatin sensitivity of human cells. Cancer Res 62: 4899-4902. (Pubitemid 34984411)
24. de las Penas R, Sanchez-Ronco M, Alberola V, Taron M, Camps C, et al. (2006) Polymorphisms in DNA repair genes modulate survival in cisplatin/gemcitabine-treated non-small-cell lung cancer patients. Ann Oncol 17: 668-675.
25. Aloyz R, Xu ZY, Bello V, Bergeron J, Han FY, et al. (2002) Regulation of cisplatin resistance and homologous recombinational repair by the TFIIH subunit XPD. Cancer Res 62: 5457-5462.
26. Yin M, Yan J, Voutsina A, Tibaldi C, Christiani DC, et al. (2011) No evidence of an association of ERCC1 and ERCC2 polymorphisms with clinical outcomes of platinum-based chemotherapies in non-small cell lung cancer: a meta-analysis. Lung Cancer 72: 370-377.
27. Qiu M, Yang X, Hu J, Ding X, Jiang F, et al. Predictive Value of XPD Polymorphisms on Platinum-Based Chemotherapy in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis. PLoS One. 2013 Aug 19;8(8):e72251.
28. Wei SZ, Zhan P, Shi MQ, Shi Y, Qian Q, et al. Predictive value of ERCC1 and XPD polymorphism in patients with advanced non-small cell lung cancer receiving platinum-based chemotherapy: a systematic review and meta-analysis. Med Oncol. 2011 Mar;28(1):315-21.
29. Cheng H, Qin Q, Sun X, Li F, Sun N, et al. (2013) Predictive Effect of XPA and XPD Polymorphisms on Survival of Advanced NSCLC Patients Treated with Platinum-based Chemotherapy: A Three-dimensional (3-D), Polyacrylamide Gel-Based DNA Microarray Method. Technol Cancer Res Treat.
30. Li XD, Han JC, Zhang YJ, Li HB, Wu XY (2013) Common variations of DNA repair genes are associated with response to platinum-based chemotherapy in NSCLCs. Asian Pac J Cancer Prev 14: 145-148.
31. Chen X, Sun H, Ren S, Kim Curran V, Zhang L, et al. (2012) Association of XRCC3 and XPD751 SNP with efficacy of platinum-based chemotherapy in advanced NSCLC patients. Clin Transl Oncol 14: 207-213.
32. Li D, Zhou Q, Liu Y, Yang Y, Li Q (2012) DNA repair gene polymorphism associated with sensitivity of lung cancer to therapy. Med Oncol 29: 1622-1628.
33. Liao WY, Shih JY, Chang GC, Cheng YK, Yang JC, et al. (2012) Genetic polymorphism of XRCC1 Arg399Gln is associated with survival in non-small-cell lung cancer patients treated with gemcitabine/platinum. J Thorac Oncol 7: 973-981.
34. Provencio M, Camps C, Cobo M, De las Penas R, Massuti B, et al. (2012) Prospective assessment of XRCC3, XPD and Aurora kinase A single-nucleotide polymorphisms in advanced lung cancer. Cancer Chemother Pharmacol 70: 883-890.
35. Wu W, Li H, Wang H, Zhao X, Gao Z, et al. (2012) Effect of polymorphisms in XPD on clinical outcomes of platinum-based chemotherapy for Chinese non-small cell lung cancer patients. PLoS One 7: e33200.
36. Ren S, Zhou S, Wu F, Zhang L, Li X, et al. (2012) Association between polymorphisms of DNA repair genes and survival of advanced NSCLC patients treated with platinum-based chemotherapy. Lung Cancer 75: 102-109.
37. Zhang ZY, Tian X, Wu R, Liang Y, Jin XY (2012) Predictive role of ERCC1 and XPD genetic polymorphisms in survival of Chinese non-small cell lung cancer patients receiving chemotherapy. Asian Pac J Cancer Prev 13: 2583-2586.
38. Ludovini V, Floriani I, Pistola L, Minotti V, Meacci M, et al. (2011) Association of cytidine deaminase and xeroderma pigmentosum group D polymorphisms with response, toxicity, and survival in cisplatin/gemcitabine- treated advanced non-small cell lung cancer patients. J Thorac Oncol 6: 2018-2026.
39. Vinolas N, Provencio M, Reguart N, Cardenal F, Alberola V, et al. (2011) Single nucleotide polymorphisms in MDR1 gen correlates with outcome in advanced non-small-cell lung cancer patients treated with cisplatin plus vinorelbine. Lung Cancer 71: 191-198.
40. Liu L, Yuan P, Wu C, Zhang X, Wang F, et al. (2011) Assessment of XPD Lys751Gln and XRCC1 T-77C polymorphisms in advanced non-small-cell lung cancer patients treated with platinum-based chemotherapy. Lung Cancer 73: 110-115.
41. Li F, Sun X, Sun N, Qin S, Cheng H, et al. (2010) Association between polymorphisms of ERCC1 and XPD and clinical response to platinum-based chemotherapy in advanced non-small cell lung cancer. Am J Clin Oncol 33: 489-494.
42. Kalikaki A, Kanaki M, Vassalou H, Souglakos J, Voutsina A, et al. (2009) DNA repair gene polymorphisms predict favorable clinical outcome in advanced non-small-cell lung cancer. Clin Lung Cancer 10: 118-123.
43. Yao CY, Huang XE, Li C, Shen HB, Shi MQ, et al. (2009) Lack of influence of XRCC1 and XPD gene polymorphisms on outcome of platinum-based chemotherapy for advanced non small cell lung cancers. Asian Pac J Cancer Prev 10: 859-864.
44. Gandara DR, Kawaguchi T, Crowley J, Moon J, Furuse K, et al. (2009) Japanese-US common-arm analysis of paclitaxel plus carboplatin in advanced non-small-cell lung cancer: a model for assessing population-related pharmacogenomics. J Clin Oncol 27: 3540-3546.
45. Booton R, Ward T, Heighway J, Taylor P, Power F, et al. (2006) Xeroderma pigmentosum group D haplotype predicts for response, survival, and toxicity after platinum-based chemotherapy in advanced nonsmall cell lung cancer. Cancer 106: 2421-2427. (Pubitemid 43787666)
46. Ryu JS, Hong YC, Han HS, Lee JE, Kim S, et al. (2004) Association between polymorphisms of ERCC1 and XPD and survival in non-small-cell lung cancer patients treated with cisplatin combination chemotherapy. Lung Cancer 44: 311-316. (Pubitemid 38609439)
47. Camps C, Sarries C, Roig B, Sanchez JJ, Queralt C, et al. (2003) Assessment of nucleotide excision repair XPD polymorphisms in the peripheral blood of gemcitabine/cisplatin-treated advanced non-small-cell lung cancer patients. Clin Lung Cancer 4: 237-241. (Pubitemid 36758173)